NCT07911683
Study Evaluating the Efficacy and Safety of BGB-B2033 in Participants With Advanced Hepatocellular Carcinoma
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Overall Response Assessment (ORR) by Independent Review Committee Assessment
Timeframe: Up to approximately 15 months
Secondary (5)
Duration of Response (DOR)
ORR by Investigator Assessment
Progression Free Survival (PFS)
Overall Survival (OS)
Number of Participants Experiencing Adverse Events (AEs), Serious Adverse Events (SAEs), and Immune-Mediated Adverse Events (iMAEs)
Arms and interventions
BGB-B2033 MonotherapyExperimental
Participants will receive BGB-B2033 intravenously until progressive disease, unacceptable toxicity, or withdrawal of consent.
Drugs: BGB-B2033